Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber Cancer Institute has agreed to pay $15 million to the U.S. government in a settlement to resolve allegations that, between 2014 and 2024, Dana-Farber violated the False Claims Act by “using fraudulent images in grant applications and research articles to induce the NIH to pay millions of dollars to support research at Dana-Farber.”

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

October 03, 2025

Vol.51 No.36

Clinical Roundup

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

A new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint, according to research gathered by the Oser Lab at Dana-Farber Cancer Institute.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer.

June 06, 2025

Vol.51 No.22

In Brief

Swim Across America grants $900,000 toward gene editing innovation

Swim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.

April 25, 2025

Vol.51 No.16

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Swim Across America grants $900,000 toward gene editing innovation

Renew today!

Subscriber content

Never miss an issue!

Login

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

YOU MAY BE INTERESTED IN

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Dana-Farber to pay $15M to U.S. government in research fraud settlement

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows

Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find

Swim Across America grants $900,000 toward gene editing innovation

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”